Changing Care Patterns for Patients with Early-Stage NSCLC

Non-small cell lung cancer is the most common type of lung cancer, accounting for 85 percent of all lung cancer diagnoses. To help multidisciplinary cancer care teams better understand and address existing barriers to care, ACCC has embarked on a national initiative to identify and provide guidance on key issues related to the care of patients diagnosed with early-stage IB/IIIA non-small cell lung cancer across different practice settings.

New research suggests there may be a potential role for epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with early-stage, resected EGFR mutation-positive non-small cell lung cancer. However, biomarker testing is not currently the standard of care for this patient population. In addition to other ACCC initiatives that address disparities in cancer care, this project will address inequities surrounding care for patients with early-stage non-small cell lung cancer by evaluating the utilization biomarker testing and treatment of patients and identifying ideal care recommendations for this population amid rapidly advancing clinical data.

It will also focus on the nuances of EGFR mutations, the utilization of biomarker testing to identify individual patient eligibility for potential EFGR TKI adjuvant therapy, and the development of efficient, guideline-concordant biomarker testing pathways for this patient population.

Phase one of the project, currently underway, focuses on garnering more insight into the barriers and challenges that can potentially influence the adoption of high-quality care for patients diagnosed with early-stage non-small cell lung cancer. The project will also incorporate recommendations for the adoption of standard resectability criteria that are replicable and scalable.

For more information on this project, please contact the ACCC Provider Education department.

FEATURED RESOURCES

OVERVIEW OF EARLY STAGE NON-SMALL CELL LUNG CANCER SURVEY RESULTS

In this survey of multidisciplinary providers across the US, ACCC assesses the current state of diagnostic, staging, and treatment practices for patients with Stage IB-IIIA non-small cell lung cancer (NSCLC). Read on to learn about the common barriers and potential responses for improving care for patients with early stage NSCLC.
Download

KEY QUALITY RECOMMENDATIONS:

Stage IB to IIIA Non-Small Cell Lung Cancer (NSCLC)

Learn about a new resource developed by expert stakeholders that incorporates evidence-based guidance on best practice in stage IB/IIIA NSCLC. The resource addresses recommendations in four core components: care coordination and patient education, diagnosis and initial management, treatment planning, and survivorship, and can be used by cancer programs to promote ideal care to patients with stage IB/IIIA NSCLC.
Download

From the ACCCBuzz Blog